Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Muscle Energetics in PAD
NCT01901224Phase 4Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of metformin in peripheral artery disease (PAD) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Change in Phosphocreatine (PCr) Recovery Time at 12 weeks. Started Jul 2013; status: terminated.
02
Drugs
metformin
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT01901224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01901224.